Poland declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Insurance
Prior authorisation, step therapy, formulary exclusion and appeal.
Poland caps semaglutide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Sweden caps liraglutide prescribing to 24 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
India declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
France caps semaglutide prescribing to 3 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Ireland caps tirzepatide prescribing to 5 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Singapore declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Germany caps liraglutide prescribing to 10 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Nigeria caps exenatide prescribing to 23 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Spain caps semaglutide prescribing to 3 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Poland declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Argentina caps semaglutide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Ireland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
South Africa caps exenatide prescribing to 20 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Norway caps exenatide prescribing to 3 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Ireland declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Kingdom declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Kingdom declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.